Assessment of commercial SARS-CoV-2 antibody assays, Jamaica. (April 2021)
- Record Type:
- Journal Article
- Title:
- Assessment of commercial SARS-CoV-2 antibody assays, Jamaica. (April 2021)
- Main Title:
- Assessment of commercial SARS-CoV-2 antibody assays, Jamaica
- Authors:
- Butterfield, Tiffany R.
Bruce-Mowatt, Alrica
Phillips, Yakima Z.R.
Brown, Nicole
Francis, Keisha
Brown, Jabari
Walker, Jerome P.
McKnight, Niel A.L.
Ehikhametalor, Kelvin
Taylor, Devon K.
Bruce, Carl A.
McGrowder, Donovan
Wharfe, Gilian
Sandiford, Simone L.
Thompson, Tamara K.
Anzinger, Joshua J. - Abstract:
- Highlights: SARS-CoV-2 antibody assays have low sensitivity for asymptomatic and mild disease Moderate to critical COVID-19 is associated with a positive antibody result High SARS-CoV-2 Ct value at diagnosis is associated with a negative antibody result Abstract: Background: The performance of the Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 IgM, Abbott Architect SARS-CoV-2 IgG, Euroimmun SARS-CoV-2 IgA, Euroimmun SARS-CoV-2 IgG ELISA, and Trillium IgG/IgM rapid assays was evaluated in Jamaica. Methods: Diagnostic sensitivities of the assays were assessed by testing serum samples from SARS-CoV-2 PCR-confirmed persons and diagnostic specificity was assessed by testing serum samples collected during 2018–2019 from healthy persons and from persons with antibodies to a wide range of viral infections. Results: Serum samples collected ≥14 days after onset of symptoms, or an initial SARS-CoV-2 RT-PCR positive test for asymptomatics, showed diagnostic sensitivities ranging from 67.9 to 75.0% when including all possible disease severities and increased to 90.0–95.0% when examining those with moderate to critical disease. Grouping moderate to critical disease showed a significant association with a SARS-CoV-2 antibody positive result for all assays. Diagnostic specificity ranged from 96.7 to 100.0%. For all assays examined, SARS-CoV-2 real-time PCR cycle threshold (Ct) values of the initial nasopharyngeal swab sample testing positive were significantly different forHighlights: SARS-CoV-2 antibody assays have low sensitivity for asymptomatic and mild disease Moderate to critical COVID-19 is associated with a positive antibody result High SARS-CoV-2 Ct value at diagnosis is associated with a negative antibody result Abstract: Background: The performance of the Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 IgM, Abbott Architect SARS-CoV-2 IgG, Euroimmun SARS-CoV-2 IgA, Euroimmun SARS-CoV-2 IgG ELISA, and Trillium IgG/IgM rapid assays was evaluated in Jamaica. Methods: Diagnostic sensitivities of the assays were assessed by testing serum samples from SARS-CoV-2 PCR-confirmed persons and diagnostic specificity was assessed by testing serum samples collected during 2018–2019 from healthy persons and from persons with antibodies to a wide range of viral infections. Results: Serum samples collected ≥14 days after onset of symptoms, or an initial SARS-CoV-2 RT-PCR positive test for asymptomatics, showed diagnostic sensitivities ranging from 67.9 to 75.0% when including all possible disease severities and increased to 90.0–95.0% when examining those with moderate to critical disease. Grouping moderate to critical disease showed a significant association with a SARS-CoV-2 antibody positive result for all assays. Diagnostic specificity ranged from 96.7 to 100.0%. For all assays examined, SARS-CoV-2 real-time PCR cycle threshold (Ct) values of the initial nasopharyngeal swab sample testing positive were significantly different for samples testing antibody positive versus negative. Conclusions: These data from a predominantly African descent Caribbean population show comparable diagnostic sensitivities and specificities for all testing platforms assessed and limited utility of these tests for persons with asymptomatic and mild infections. … (more)
- Is Part Of:
- International journal of infectious diseases. Volume 105(2021)
- Journal:
- International journal of infectious diseases
- Issue:
- Volume 105(2021)
- Issue Display:
- Volume 105, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 105
- Issue:
- 2021
- Issue Sort Value:
- 2021-0105-2021-0000
- Page Start:
- 333
- Page End:
- 336
- Publication Date:
- 2021-04
- Subjects:
- COVID-19 -- SARS-CoV-2 -- Antibody -- Serology -- Caribbean -- Jamaica
Communicable diseases -- Periodicals
Communicable Diseases -- Periodicals
Communicable diseases
Periodicals
Electronic journals
616.9 - Journal URLs:
- http://bibpurl.oclc.org/web/73769 ↗
http://www.journals.elsevier.com/international-journal-of-infectious-diseases/ ↗
http://www.sciencedirect.com/science/journal/12019712 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/12019712 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/12019712 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ijid.2021.02.059 ↗
- Languages:
- English
- ISSNs:
- 1201-9712
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.304750
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22499.xml